| SIGHT Stock | | | EUR 0.26 0.01 4.00% |
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out
World Market Map to better understand how to build diversified portfolios, which includes a position in Gensight Biologics SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in estimate.
Gensight Biologics SA Company Z Score Analysis
Gensight Biologics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Current Gensight Biologics Z Score | | | | 6.6 |
Most of Gensight Biologics' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gensight Biologics SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
| First Factor | = | 1.2 * ( | Working Capital | / | Total Assets ) |
|
| Second Factor | = | 1.4 * ( | Retained Earnings | / | Total Assets ) |
|
| Thrid Factor | = | 3.3 * ( | EBITAD | / | Total Assets ) |
|
| Fouth Factor | = | 0.6 * ( | Market Value of Equity | / | Total Liabilities ) |
|
| Fifth Factor | = | 0.99 * ( | Revenue | / | Total Assets ) |
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Based on the company's disclosures, Gensight Biologics SA has a Z Score of 6.6. This is 2.22% lower than that of the Biotechnology sector and 97.6% higher than that of the
Health Care industry. The z score for all France stocks is 24.31% higher than that of the company.
Gensight Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gensight Biologics' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gensight Biologics could also be used in its relative valuation, which is a method of valuing Gensight Biologics by comparing valuation metrics of similar companies.
Gensight Biologics is currently under evaluation in z score category among its peers.
Gensight Fundamentals
About Gensight Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gensight Biologics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gensight Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at
the intrinsic value of Gensight Biologics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing
financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our
fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Gensight Stock Analysis
When running Gensight Biologics' price analysis, check to
measure Gensight Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gensight Biologics is operating at the current time. Most of Gensight Biologics' value examination focuses on studying past and present price action to
predict the probability of Gensight Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gensight Biologics' price. Additionally, you may evaluate how the addition of Gensight Biologics to your portfolios can decrease your overall portfolio volatility.